Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.

Hamilton BK, Pandya BJ, Ivanescu C, Elsouda D, Hamadani M, Chen YB, Levis MJ, Ueda Oshima M, Litzow MR, Soiffer RJ, Ustun C, Perl AE, Singh AK, Geller N, Hasabou N, Rosales M, Cella D, Corredoira L, Pestana C, Horowitz MM, Logan B

Open source

DOI: 10.1182/bloodadvances.2024013746
Published: 2024 Oct 8
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2024013746,
  title = {Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.},
  author = {Hamilton BK and Pandya BJ and Ivanescu C and Elsouda D and Hamadani M and Chen YB and Levis MJ and Ueda Oshima M and Litzow MR and Soiffer RJ and Ustun C and Perl AE and Singh AK and Geller N and Hasabou N and Rosales M and Cella D and Corredoira L and Pestana C and Horowitz MM and Logan B},
  year = {2024},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2024013746},
  url = {https://doi.org/10.1182/bloodadvances.2024013746}
}

RIS

TY  - JOUR
TI  - Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.
AU  - Hamilton BK
AU  - Pandya BJ
AU  - Ivanescu C
AU  - Elsouda D
AU  - Hamadani M
AU  - Chen YB
AU  - Levis MJ
AU  - Ueda Oshima M
AU  - Litzow MR
AU  - Soiffer RJ
AU  - Ustun C
AU  - Perl AE
AU  - Singh AK
AU  - Geller N
AU  - Hasabou N
AU  - Rosales M
AU  - Cella D
AU  - Corredoira L
AU  - Pestana C
AU  - Horowitz MM
AU  - Logan B
PY  - 2024
JO  - Blood advances
DO  - 10.1182/bloodadvances.2024013746
UR  - https://doi.org/10.1182/bloodadvances.2024013746
ER  -

APA

BK, H., BJ, P., C, I., D, E., M, H., YB, C., MJ, L., M, U. O., MR, L., RJ, S., C, U., AE, P., AK, S., N, G., N, H., M, R., D, C., L, C., C, P., MM, H., & B, L. (2024). Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.. Blood advances. https://doi.org/10.1182/bloodadvances.2024013746

Source records

pubmed · retrieved 2026-09-26T07:44:42.802Z